Drugs / TERTOMOTIDE

Trials 16 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT06625710 Oct 2024 → Aug 2025 neurodegenerative disease GemVax & Kael Completed No outcome recorded
Phase 1 NCT01342224 Jan 2011 → Jun 2012 pancreatic adenocarcinoma Providence Health & Services Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01247623 Jan 2005 → Sep 2011 melanoma Oslo University Hospital Completed No outcome recorded
Phase 27 trials
Phase 2 NCT06235775 Dec 2023 → Sep 2025 progressive supranuclear palsy GemVax & Kael Completed No outcome recorded
Phase 2 NCT05819658 Jun 2023 → Oct 2024 progressive supranuclear palsy GemVax & Kael Completed No outcome recorded
Phase 2 NCT05189210 Oct 2022 → Apr 2025 GemVax & Kael Completed No outcome recorded
Phase 2 NCT03959553 Sep 2019 → Aug 2021 Alzheimer disease GemVax & Kael Withdrawn No outcome recorded
Phase 2 NCT03184467 Sep 2017 → Sep 2019 Alzheimer disease GemVax & Kael Completed No outcome recorded
Phase 2 NCT02855892 Oct 2015 → Oct 2016 benign prostatic hyperplasia GemVax & Kael Completed No outcome recorded
Phase 2 NCT00444782 Nov 2006 → Apr 2008 hepatocellular carcinoma Pharmexa A/S Completed No outcome recorded
Phase 35 trials
Phase 3 NCT05303701 Jul 2027 → Jan 2028 expected Alzheimer disease Samsung Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT02854072 Nov 2015 → May 2018 malignant pancreatic neoplasm Samsung Pharmaceutical Co., Ltd. Unknown No outcome recorded
Phase 3 NCT01579188 May 2012 → May 2016 non-small cell lung carcinoma Kael-GemVax Co., Ltd. Unknown No outcome recorded
Phase 3 NCT00425360 Sep 2006 → Mar 2013 malignant pancreatic neoplasm Royal Liverpool University Hospital Completed No outcome recorded
Phase 3 NCT00358566 Jun 2006 → Aug 2008 malignant pancreatic neoplasm Pharmexa A/S Terminated No outcome recorded
Phase not applicable1 trial
NCT00509457 Nov 2006 → Aug 2009 non-small cell lung carcinoma Oslo University Hospital Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01223209 Background Aug 2010 → Dec 2011 carcinoma Lytix Biopharma AS Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as TERTOMOTIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2108308
Known as GV1001 GV1001 is a peptide vaccine in development to treat cancer.” NCT01223209
16

“telomerase vaccine: GV1001NCT01342224

NCT03959553

NCT05189210

NCT00509457

NCT05303701

NCT06625710

NCT00425360

NCT02854072

NCT02855892

NCT00444782

NCT01247623

NCT03184467

NCT05819658

NCT01579188

NCT00358566

NCT06235775

Known as Htert (534-549) ChEMBL registry synonym — accepted as the source's own label CHEMBL2108308
Known as Tertomotida ChEMBL registry synonym — accepted as the source's own label CHEMBL2108308
Action Inhibit “GV1001 inhibits neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta (Aβ)” NCT05303701
Modality Vaccine “telomerase peptide vaccine GV1001” NCT00425360
Route Other “telomerase peptide vaccine GV1001 ID on days 1, 3, and 5 in week 9” NCT00425360